查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971451

虫媒病毒检测市场－全球产业规模、份额、趋势、机会与预测：按检测类型、最终用户、地区和竞争格局划分，2021-2031年

Arbovirus Testing Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (RT-PCR Test, ELISA-Test), By End User (Hospitals, Diagnostic Centers), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球虫媒病毒检测市场预计将从 2025 年的 20.7 亿美元成长到 2031 年的 29.2 亿美元，复合年增长率为 5.91%。

此领域涵盖诊断检测和试剂，例如RT-PCR和ELISA试剂盒，旨在识别由蜱虫和蚊子等节肢动物传播的感染疾病。推动这一领域成长的主要因素是基孔肯雅热、兹卡病毒病和登革热等媒介传播感染疾病的发病率不断上升，而快速的都市化和气候变迁导致的媒介栖息地扩张进一步加剧了这一趋势。此外，政府加大对公共卫生监测的投入，并开发旨在透过快速且准确的诊断能力有效控制疫情的早期预警系统，也促进了市场的发展。

市场概览
预测期 2027-2031
市场规模：2025年 20.7亿美元
市场规模：2031年 29.2亿美元
复合年增长率：2026-2031年 5.91%
成长最快的细分市场 ELISA检测
最大的市场 北美洲

然而，该市场面临一项重大挑战：血清学检测中的抗体交叉反应，这常常导致假阳性结果，并阻碍在多种虫媒病毒共存地区进行准确诊断。这项技术难题凸显了对能够区分密切相关病毒株的高特异性诊断设备的迫切需求。根据欧洲疾病预防控制中心 (ECDC) 2024 年发布的数据，「全球报告的登革热病例超过 1400 万例，登革热相关死亡病例超过 1 万例。」 这些统计数据表明，登革热给社会带来了巨大的负担，并强调了建立强大且扩充性的检测基础设施的迫切需求。

市场驱动因素

气候变迁和蚊虫栖息地扩张导致病原体入侵先前未受感染地区，进而引发全球虫媒病毒感染疾病激增，这大大刺激了市场需求。日益加重的疾病负担凸显了对能够检测和识别除传统流行病之外的新威胁的诊断测试的需求。例如，泛美卫生组织（PAHO）在其2024年12月发布的最新报告《美洲登革热和奥罗普西热病例数创历史新高》中指出，2024年该地区确诊的奥罗普西热病例达11600例，较上年的832例显着增加。感染率的快速成长迫使卫生部门采购先进的检测套组以应对复杂的流行病学环境，直接推动了全球诊断产品的消费。

此外，政府加大对公共卫生监测的投入是关键驱动力，为检测设施现代化和防治媒介传播疾病提供了必要的财政支持。联邦和国际组织正在投入大量资金，以确保检测实验室拥有有效监测和应对疫情所需的设备。根据美国兽医学院协会（AAVMC）2025年4月发布的公告，美国疾病管制与预防中心（CDC）媒介传播感染疾病科在2025财政年度获得了9,060万美元的预算拨款，用于支持预防和监测活动。这项财政投入在全球范围内意义重大。核能（IAEA）于2025年10月发布的《2024年度报告》重点介绍了ZODIAC倡议如何为约40家兽医检查室配备了用于防治通用感染疾病疫情的诊断设备，并直接创造了对血清学和分子检测解决方案的持续需求。

市场挑战

血清学诊断工具固有的交叉反应性是虫媒病毒检测产业商业性发展的一大障碍。当检测无法正确区分抗体和结构相似的病毒时，就会出现这个问题，导致假阳性率居高不下。此类误差会降低终端用户的信心，需要额外的确认性检测，最终导致医疗成本增加和诊断时间延长。因此，在那些需要准确诊断以保障病人安全的地区，快速血清学试剂盒的推广应用面临重重困难。

需要进行鑑别诊断的病例数庞大，凸显了这项挑战的严峻性。根据泛美卫生组织2024年的报告，「美洲报告了超过1,100万例疑似登革热病例」。在如此高的发病率下，标准检测方法无法区分登革热与其他同时发生的虫媒病毒，导致诊疗工作延误。这种特异性不足限制了现有检测产品的扩充性，并损害了高需求地区的商机。

市场趋势

自动化、高通量检测系统的应用正从根本上改变全球虫媒病毒检测市场，打造出能够应对疫情期间诊断需求激增的临床实验室环境。随着感染率的上升，製造商正致力于开发全自动免疫检测，以确保优化工作流程并快速报告结果，这对于高效的患者照护至关重要。近期监管机构核准的、能够以最少的人工干预处理海量检体的系统，凸显了向高容量基础设施的转变。例如，在2025年10月发布的新闻稿《罗氏新型自动化高通量Elecsys登革热抗原检测获得CE认证》中，罗氏宣布其自动化抗原检测获得认证，该检测仅需18分钟即可出结果，显着提高了高需求地区的效率。

同时，先进的微流体和生物感测器平台正在解决一个关键的产业挑战：血清学交叉反应。该领域的发展利用创新的微球技术和生物感测接口，能够准确区分结构相似的黄病毒，例如登革热病毒和兹卡。这些病毒经常与传统检测方法混淆，但先进的平台具有更高的特异性，可以降低假阳性结果的临床影响，并支持更精准的流行病学监测。例如，北卡罗来纳大学教堂山分校在其2025年2月发表的论文《一种能够准确诊断和监测登革热病毒和兹卡病毒的新型检测方法》中报告称，他们开发的多微球检测方法在识别既往登革热感染方面达到了94.9%的灵敏度，同时还能成功将其与兹卡病毒抗体区分开来。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：虫媒疾病病毒检测的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依检测类型（RT-PCR 检测、ELISA 检测）
    • 依最终用户（医院、诊断中心）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美虫媒病毒检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲虫媒病毒检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区虫媒病毒检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲虫媒病毒检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲虫媒病毒检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球虫媒病毒检测市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Becton Dickinson & Co
  • bioMerieux SA
  • Abbott Laboratories Inc.
  • Quidel Corporation
  • OraSure Technologies, Inc.
  • Hologic Inc.
  • Cepheid
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24013

The Global Arbovirus Testing Market is projected to expand from USD 2.07 Billion in 2025 to USD 2.92 Billion by 2031, reflecting a compound annual growth rate of 5.91%. This sector encompasses diagnostic assays and reagents, such as RT-PCR and ELISA kits, designed to identify infections spread by arthropod vectors like ticks and mosquitoes. A primary catalyst for this growth is the rising incidence of vector-borne illnesses, including Chikungunya, Zika, and Dengue, which is further aggravated by rapid urbanization and climate change expanding vector territories. Furthermore, the market is bolstered by increased government investment in public health surveillance and the establishment of early warning systems aimed at effectively managing outbreaks through rapid and precise diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.07 Billion
Market Size 2031USD 2.92 Billion
CAGR 2026-20315.91%
Fastest Growing SegmentELISA-Test
Largest MarketNorth America

However, the market faces a significant obstacle regarding the cross-reactivity of antibodies in serological testing, which frequently results in false positives and hinders accurate diagnosis in areas where multiple arboviruses are present simultaneously. This technical shortcoming highlights a critical demand for highly specific diagnostic instruments capable of distinguishing between closely related viral strains. As reported by the 'European Centre for Disease Prevention and Control' in '2024', there were 'over 14 million dengue cases and over 10,000 dengue-related deaths were reported globally', a statistic that underscores the massive disease burden and the imperative for durable, scalable testing infrastructures.

Market Driver

The escalating global prevalence of arboviral infections acts as a major market stimulant, fueled by climate change and the widening reach of mosquito habitats that introduce pathogens to previously unaffected areas. This growing disease burden necessitates diagnostic assays that can detect and differentiate emerging threats beyond standard outbreaks. For example, the Pan American Health Organization noted in a December 2024 update titled 'Americas report record dengue and Oropouche cases' that 11,600 Oropouche cases were documented in the region during 2024, a stark rise from only 832 cases the previous year. Such a sharp increase in infection rates compels health authorities to acquire advanced testing kits to navigate the complex epidemiological environment, thereby directly boosting the global consumption of diagnostic products.

Additionally, increasing government funding for public health surveillance serves as a crucial driver, providing the financial support needed to modernize laboratory facilities and vector control initiatives. Both federal and international organizations are dedicating significant funds to ensure laboratories possess the necessary equipment to monitor and address outbreaks efficiently. According to the American Association of Veterinary Medical Colleges in April 2025, the CDC's Division of Vector-Borne Diseases received appropriations of $90.6 million for the 2025 fiscal year to aid prevention and surveillance efforts. This financial dedication is evident globally; the International Atomic Energy Agency's 'Annual Report 2024', released in October 2025, highlighted that the ZODIAC initiative outfitted nearly 40 veterinary laboratories with diagnostic gear to fight zoonotic outbreaks, directly creating sustained demand for serological and molecular testing solutions.

Market Challenge

The inherent cross-reactivity found in serological diagnostic tools poses a significant barrier to the commercial advancement of the arbovirus testing industry. This issue occurs when assays cannot correctly distinguish between antibodies of structurally analogous viruses, resulting in a high rate of false-positive outcomes. Such inaccuracies diminish end-user trust and require supplementary confirmatory testing, which ultimately increases healthcare costs and prolongs the time required for diagnosis. As a result, the uptake of rapid serological kits faces difficulties in gaining traction in areas where precise diagnosis is essential for patient safety.

The severity of this challenge is emphasized by the massive number of cases that require differentiation. As stated by the 'Pan American Health Organization' in '2024', 'the Region of the Americas reported more than 11 million suspected cases of dengue'. In settings burdened by such high disease rates, the failure of standard tests to separate dengue from other co-circulating arboviruses causes operational delays. This deficiency in specificity restricts the scalability of existing testing products and curtails revenue opportunities in geographical regions with high demand.

Market Trends

The adoption of automated high-throughput laboratory systems is fundamentally reshaping the Global Arbovirus Testing Market by allowing clinical labs to handle the increasing load of diagnostic requests during intense outbreak periods. As transmission rates rise, manufacturers are focusing on creating fully automated immunoassays that optimize workflows and guarantee quick turnaround times, which are vital for efficient patient care. This move towards high-capacity infrastructure is highlighted by recent regulatory clearances for systems capable of processing vast sample quantities with little human involvement; for instance, Roche announced in an October 2025 press release titled 'Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue' that it obtained certification for an automated antigen test providing results in only 18 minutes, greatly improving efficiency in high-demand areas.

Concurrently, the advancement of sophisticated microfluidic and biosensor platforms is tackling the significant industry hurdle of serological cross-reactivity. Developments in this sector employ innovative microsphere technologies and biosensing interfaces to attain exact differentiation between structurally alike flaviviruses, such as Dengue and Zika, which conventional assays frequently confuse. These advanced platforms deliver superior specificity, decreasing the clinical impact of false positives and aiding more precise epidemiological monitoring. For example, the University of North Carolina at Chapel Hill reported in a February 2025 article, 'New Assay Promises Accurate Diagnosis and Surveillance of Dengue and Zika Viruses', that researchers developed a multiplex microsphere assay achieving 94.9% sensitivity in identifying past dengue infections while successfully distinguishing them from Zika antibodies.

Key Market Players

  • Becton Dickinson & Co
  • bioMerieux SA
  • Abbott Laboratories Inc.
  • Quidel Corporation
  • OraSure Technologies, Inc.
  • Hologic Inc.
  • Cepheid
  • QIAGEN N. V.
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Arbovirus Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Arbovirus Testing Market, By Test Type

  • RT-PCR Test
  • ELISA-Test

Arbovirus Testing Market, By End User

  • Hospitals
  • Diagnostic Centers

Arbovirus Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Arbovirus Testing Market.

Available Customizations:

Global Arbovirus Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Arbovirus Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (RT-PCR Test, ELISA-Test)
    • 5.2.2. By End User (Hospitals, Diagnostic Centers)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Arbovirus Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Arbovirus Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Arbovirus Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Arbovirus Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End User

7. Europe Arbovirus Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Arbovirus Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Arbovirus Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Arbovirus Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Arbovirus Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Arbovirus Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Arbovirus Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Arbovirus Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Arbovirus Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Arbovirus Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Arbovirus Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Arbovirus Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Arbovirus Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Arbovirus Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Arbovirus Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Arbovirus Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End User

10. South America Arbovirus Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Arbovirus Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Arbovirus Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Arbovirus Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Arbovirus Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton Dickinson & Co
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. bioMerieux SA
  • 15.3. Abbott Laboratories Inc.
  • 15.4. Quidel Corporation
  • 15.5. OraSure Technologies, Inc.
  • 15.6. Hologic Inc.
  • 15.7. Cepheid
  • 15.8. QIAGEN N. V.
  • 15.9. F. Hoffmann-La Roche Ltd.
  • 15.10. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer